

**A Call to Action:
Assessing New Standards of Care in Advanced Head and Neck Cancer**

Proposed Symposium at the AHNS 2008 Annual Meeting

1. PROGRAM

- | | | |
|---------|--|---|
| 6:30 am | Welcome and introductory remarks | <i>Marshall Posner
(Chair)</i> |
| 6:40 am | First-line therapeutic options:
Considerations for the selection of therapy <ul style="list-style-type: none">• Chemo-radiotherapy• Hyperfractionated / accelerated RT• Induction chemotherapy: An update• Radiotherapy + EGFR inhibitors• Chemoradiotherapy + EGFR inhibitors (?)• Efficacy / safety / QoL | <i>Paul Harari
(OR
Barbara Murphy)</i> |
| 7:00 am | Therapeutic options for relapsed/metastatic disease:
Opportunities for improved outcomes <ul style="list-style-type: none">• Chemotherapy• Chemotherapy + EGFR inhibitors• EGFR inhibitors | <i>Marshall Posner</i> |
| 7:20 am | Selecting patients for therapy:
Are there any biochemical or clinical markers for
prognosis or response? <ul style="list-style-type: none">• Prognostic markers• Correlates with response to chemotherapy (brief)• Lack of correlation of response with IHC• FISH as a predictor of disease severity and / or responsiveness?• PCR – will this have any role?• K-RAS mutations: Any lessons from CRC• Clinical indicators: Rash | <i>Corey Langer</i> |
| 7:40 am | Take Home Perspectives:
Integrating approaches to individualize therapy | <i>Panel discussion</i> |
| 8:00 am | Close | |

2. PROPOSED FACULTY

The proposed Faculty for this activity is:-

- Marshall R. Posner, MD (Chair), Associate Professor of Medicine, Harvard Medical School, Medical Director of the Head and Neck Oncology Program, Dana-Farber Cancer Institute, Boston, MA

- Corey J Langer, MD, Director, Thoracic and Head and Neck, Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA
- Paul M. Harari, MD, Professor and Chair of Department of Human Oncology, University of Wisconsin School of Medicine, Madison, WI
Or
- Barbara Murphy, MD, Associate Professor of Medicine, Director, Head and Neck Research Program, Vanderbilt-Ingram Cancer Center, Nashville, TN

3. LEARNING OBJECTIVES

At the conclusion of this activity, participants should be better able to:-

- Cite the evidence for various therapeutic approaches for the first-line therapy of advanced head and neck cancer, including chemotherapy, radiotherapy, EGFR-targeted therapy, and combinations
- Cite recent data regarding the impact of management options for relapsed or metastatic head and neck cancer on survival
- Describe how molecular markers correlate with prognosis and/or response to therapy
- Predict how molecular or clinical markers, could be used in the selection of therapy for individual patients

4. INVITATION PROCESS

Recruitment for the symposium will be driven through a number of methods. An initial 4-panel, full color flyer will be mailed to the pre-registration list supplied by the AHNS. We would also like to take advantage of the AHNS offer to place symposia will also be on the AHNS website and within the program schedule and final program.

Advance registrations for the symposium will be possible via post, fax, or on-line at scicme.com.

If possible, we would also like to disseminate flyers on site (e.g. door drop, delegates bag as allowed by AHNS).

5. TARGET AUDIENCE

This CME-certified activity has been planned for oncologists, radiation oncologists and surgical oncologists involved in the management of patients with head and neck cancer. This activity will also be of interest to oncology nurses, and other healthcare professionals, and to research scientists all of whom are welcome to attend.